Shire plc: Non Executive Director Appointment

Shire plc: Non Executive Director Appointment

SOURCE Shire plc

DUBLIN, October 23, 2013 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), announces that Dominic Blakemore will join its Board of Directors effective 1 January 2014 as non executive director and member of the Audit, Compliance & Risk Committee.

     (Photo: http://photos.prnewswire.com/prnh/20131023/648208 )
Dominic is Group Finance Director of Compass Group PLC.  Prior to this he was Chief Financial Officer at Iglo Foods Group and Finance & Strategy Director of Cadbury plc. He spent his earlier career years at PwC (PricewaterhouseCoopers), where his work included advising pharmaceutical sector clients.

Matthew Emmens, Chairman of Shire commented:

"The Shire Board will benefit from Dominic's strategic and financial experience. We look forward to him joining the Board."

Dominic Blakemore added:

"Shire has an excellent track record of growth and a clear strategy. I look forward to playing a part in this growing company's future."

There is no further information that is required to be disclosed under 9.6.13R of the UK Listing Rules.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.


http://www.shire.com

For further information please contact:

Investor Relations       
Eric Rojas   
[email protected]   
+1-781-482-0999
Sarah Elton-Farr   
[email protected]   
+44-1256-894157

Media       
Jessica Mann   
[email protected]   
+44-1256-894-280

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.